|
|
Article: PathoGenesis Corp. Begins Clinical Trial Of TOBI in Cystic Fibrosis Patients With Mild Lung Disease.
- Article from:
- PR Newswire
- Article date:
- May 30, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, May 30 /PRNewswire/ --
PathoGenesis Corp. (Nasdaq: PGNS) has begun to enroll patients in an open-label, randomized Phase IV clinical trial of TOBI(R) (tobramycin solution for inhalation) in cystic fibrosis patients with mild lung disease.
PathoGenesis plans to enroll up to 400 people, ages 6-15, who have cystic fibrosis (CF) and Pseudomonas aeruginosa lung infections but who have not yet experienced a major decline in lung function. At the beginning of the trial, patients' pulmonary function will be 70 percent to 90 percent of normal levels, as defined by forced expiratory volume at one second (FEV1). The 14-month study will compare patients ...